[Lymph-node toxoplasmosis: recent clinical, diagnostic and therapeutic acquisitions].
D000890:Anti-Infective Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007244:Infectious Mononucleosis / Q000175:diagnosis; D008198:Lymph Nodes / Q000473:pathology; D008206:Lymphatic Diseases / Q000175:diagnosis* / Q000188:drug therapy; D008223:Lymphoma / Q000175:diagnosis; D011739:Pyrimethamine / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*; D014123:Toxoplasmosis / Q000175:diagnosis* / Q000188:drug therapy; D014295:Trimethoprim / Q000627:therapeutic use
D000890:Anti-Infective Agents; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D013449:Sulfonamides; D014295:Trimethoprim; D013420:Sulfamethoxazole; D011739:Pyrimethamine
La toxoplasmosi linfoghiandolare: recenti acquisizioni cliniche, diagnostiche e terapeutiche.